Genfleet Therapeutics (shanghai), Inc. Class H · HKEX:2595
Genfleet Therapeutics (shanghai), Inc. Class H — GenFleet Therapeutics — H1 2026 Earnings Presentation
32 slides from Genfleet Therapeutics (shanghai), Inc. Class H's earnings presentation, August 2026
Slide 1: GenFleet Therapeutics 2026 Interim Results
GenFleet Therapeutics (2595.HK） 2026 Interim Results Aug. 2026
Slide 2: Copyright, Disclaimer and Forward-looking Statements
Copyright, Disclaimer and Forward-looking Statements Specific information in this presentation may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as "predict", "believe", "plan", "predict", "expect", "will"
Slide 3: Company Overview and Interim Results
O07 Company Overview and Interim Results
Slide 4: RAS-inhibiting Therapeutics Represent Unprecedented Multi-billion Oncology Market Opportunity
RAS-inhibiting Therapeutics Represent Unprecedented Multi-billion Oncology Market Opportunity in Decades KRAS NRAS HRAS Source：Frost Sullivan 481.8 131.4 43.8 Forecast of RAS- or 137.8 G12D EGFR-mutated patients 30% 113.2 G12V Forecast of RAS-inhibiting RAS therapeutics market reaches 68.8 G12C muta
Slide 5: Global RAS Inhibitor Market Forecasted to Reach Nearly USD 7 Bn in 2034
Global RAS Inhibitor Market Forecasted to Reach Nearly USD 17 Bn in 2034 10-year CAGR: 9.5% 180 168 in USD 100 MM 160 Source: datainteloanalysis 137 140 120 112 100 89 80 74 59 60 38 40 28 20 0 2019 2021 2023 2025 2027 2029 2031 2034 5
Slide 6: Leading Position of GenFleet's RAS-inhibiting Therapies across Modalities
Leading Position of GenFleet’s RAS-inhibiting Therapies across Modalities Front-runners in China’s clinical development Target No.1 No.2 No.3 KRAS G12C Fulzerasib（No. 3 globally） Garsorasib Glecirasib Switch II GFH375 (global leader in oral G12Di dev’t: Ph III mono, other combo trials） DN022150 pock
Slide 7: GenFleet Leverages Diverse Technologies to Deliver Differentiated Advantages
GenFleet Leverages Diverse Technologies to Deliver Differentiated Advantages over Global Leader of RAS-targeted Therapeutics Commercial stage Company stage Clinical stage Multi-pronged RAS inhibition: Matrix of RAS (ON) inhibitors innovative NMEs of diverse modalities RAS-targeted Focused, original
Slide 8: Interim Financial Highlights: Significant reduction in periodic loss
Interim Financial Highlights: Significant reduction in periodic loss, with Sustained Revenue & Cash Reserves Overall revenue in H1 R&D costs rising alongside pipeline size, with Significant reduction in periodic loss （in ten thousands RMB) notable fall in admin costs (in ten thousands RMB) （in 100 m
Slide 9: 2026 Progress: Clinical Acceleration & Financial Stability
2026 Progress: Clinical Acceleration & Financial Stability Multiple IND approvals for late-stage trials, fortifying GFH375: World's first ph III-oral KRAS G12D inhibitor GenFleet’s RAS leading-edge pipeline Two Breakthrough Therapy Designations obtained (PDAC & NSCLC Multi-target, multi-molecula
Slide 10: Company Pipeline and Progress
WA, Company Pipeline and Progress
Slide 11: Highly Differentiated Pipeline with Validated Prospects
Highly Differentiated Pipeline with Validated Prospects RAS-targeted matrix and diversified innovative treatments Marketed Ph3 ongoing Ph3 expected to start in 2027 Others Study GenFleet’ Compound Target Indication Preclinical IND-enabling Ph I Ph II Ph III NDA Approval Partner Location Rights Oncol
Slide 12: GFH375: Global Leader in Oral KRAS G12D Inhibitor Development
GFH375 (Switch II Pocket KRAS Inhibitor): Global Leader in Oral KRAS G12D Inhibitor Development Two registrational studies: world’s first phase III oral KRAS G12D inhibitor in pancreatic cancer and NSCLC; extensive clinical program includes mono/combo regimens, 1L/later-line trials Efficient advance
Slide 13: Consecutive Selections of GFH375's Clinical Data into Oral Presentation Sessions
Consecutive Selections of GFH375’s Clinical Data into Oral Presentation Session at Top-tier Global Academic Meetings Solid NSCLC tumors 2025 ASCO 2025 WCLC CCA & PDAC CRC 2025 ESMO 2026 ASCO 13
Slide 14: Robust Druggability Supported by Consistent Efficacy and Safety Profile
Robust Druggablity Supported by Consistent Efficacy and Safety Profile GFH375’s promising efficacy across multiple malignancies earns commentator recognition at 2026 ASCO We see a truly impressive response rate in CCA, a refractory disease. And I will mention that we saw data earlier for this agent
Slide 15: GFH375: Best Efficacy at Lowest Oral RP2D Dose Level in PDAC
GFH375: Best Efficacy at Lowest Oral RP2D Dose Level in KRAS G12Di Monotherapy PDAC Trials Cross-trial comparison Company Product RP2D Sample size ORR DCR PFS OS Data source 600 mg 5.52m; 4-m rate: GenFleet GFH375 59 40.7% 96.7% 2025 ESMO QD 4-m rate: 78.2% 92.2% DN022150 650 mg Kerui 31 41.9% 93.5%
Slide 16: GFH375: Best Efficacy at Lowest Oral RP2D Dose Level in NSCLC
GFH375: Best Efficacy at Lowest Oral RP2D Dose Level in KRAS G12Di Monotherapy NSCLC Trials Cross-trial comparison Sample Company Product RP2D ORR DCR PFS OS Data source size 600 mg GenFleet GFH375 16 68.8% 93.8% / / 2025 WCLC QD 44.4% 88.9% 1200 mg Tyligand TSN1611 27 600-1200 mg BID / / 2026 ASCO
Slide 17: Registrational Phase III Studies Accelerating with Top-tier Experts
Registrational Phase III Studies Accelerating in Collaboration with Top-tier Experts Investigators’ meeting for GFH375X1301 (Kylin-Wings 01) Investigators’ meeting for GFH375X1303 (Kylin-Flight 01) study initiation - GFH375’s ph3 mono trial in PDAC study initiation - GFH375’s ph3 mono trial in NSCLC
Slide 18: GFH276: Top-tier in China's Pan RAS Inhibitor Development
GFH276 (Molecular Glue Pan RAS Inhibitor) Top-tier in China’s Pan RAS Inhibitor Development First-tier development of Pan RAS inhibitor in China: first patient dosed in Sept. 2025; first-line combination therapy to be initiated in China and Australia this year, with three combination regimens for PD
Slide 19: GFH276: Human PK & Safety Profile versus RMC-6236
GFH276: Human PK & Safety Profile Demonstrates a Broader Potential Therapeutic Window versus RMC-6236 Indication for available data RAS mutant tumors PDAC Lowest dosage with observed efficacy GFH276 (Undisclosed) RMC-6236 (80 mg QD) Grade ≥3 TRAEs Not observed Observed Rash incidence All G1 Grade 1-2
Slide 20: GFH276's Global Development Strategy after RP2D Confirmation
GFH276’s Global Dev’t Strategy after RP2D Confirmation in China’s Study Fast track into 1L setting: PDAC & NSCLC To gain traction in treatment of CRC • Combo with cetuximab: supported by • Safety advantage: no ≥G3 skin TRAE KRAS+EGFR POC in PhII data of GenFleet’s • Combo potential: with cetuximab E
Slide 21: GFS202A: World's First Bispecific Antibody Therapy for Cachexia
GFS202A (GDF15/IL-6 Bispecific Antibody): World's First Bispecific Antibody Therapy for Cachexia Globally innovative combo & preliminary efficacy: world’s first clinical-stage bispecific antibody cachexia; early efficacy supports upcoming combo trials Dual-pathway advantage: inhibiting GDF15 and IL-
Slide 22: GFS202A Trial Shows Dose-dependent Weight Gain
Feature Report of Nature on Cancer Cachexia: GFS202A Trial Shows Dose-dependent Weight Gain Consistent With the Ponsegromab Trial Dose-dependent weight gain An average of at least 5% weight gain was observed at 200 mg Q3W dose level and above after administration of GFS202A for 6 weeks, suggesting i
Slide 23: Encouraging Efficacy in GFS202A's Phase I Data
Encouraging Efficacy in GFS202A’s Phase I data, with Dose-dependent Increase in Skeletal Muscle Mass L3SMI by IRC at Week 6 Case study Baseline Week 6 • Female, 71 yrs old, gallbladder Efficacy at Week 6 cancer • Prior antitumor therapy: GEMOX The mean L3 skeletal muscle index (L3SMI) • On-treatment
Slide 24: Innovation Highlights and Market Prospects
O03 Innovation Highlights and Market Prospects
Slide 25: Full-RAS and Cachexia Pipeline Enable Two Distinct Combo Strategies
Leveraging GenFleet's Unique Full-RAS and Cachexia Pipeline to Enable Two Distinct Combo Strategies World’s first RAS combo pairing World’s first combo of RASi + two inhibitors with distinct MOAs cachexia-targeting bispecific antibody GFH375 + GFH276 GFH375 + GFS202A Phase II IND application approve
Slide 26: GFH375 + GFH276: First-in-world Combo of RAS Inhibitors
GFH375 + GFH276: First-in-world Combo of RAS Inhibitors with Distinct MOA Rev Med trial: dual molecular-glue combination (RMC-9805+RMC-6236) • ORR: superior to each single-agent monotherapy • Preliminary clinical validation of combining KRAS G12D + Pan RAS dual inhibition Data source：2026 ESMO GI Pr
Slide 27: Pancreatic Cancer & Cachexia Therapeutics Forecasted at Multi-Billion Scale
Pancreatic Cancer & Cachexia Therapeutics Forecasted at Multi-Billion Scale in the Next Decade Forecasted global incidence of pancreatic cancer Forecasted global market of pancreatic cancer therapeutics Source: Frost Sullivan (in 10 thousands) Source: Research Nester (100 million USD) CAGR 2.6% 73.5
Slide 28: RAS-inhibiting Therapeutics Represent Multi-billion USD Oncology Market Opportunity
RAS-inhibiting Therapeutics Represent Unprecedented Multi-billion USD Oncology Market Opportunity in Decades KRAS NRAS HRAS Source：Frost Sullivan 481.8 131.4 43.8 Forecast of RAS- or 137.8 G12D EGFR-mutated patients 30% 113.2 G12V Forecast of RAS-inhibiting RAS therapeutics market reaches 68.8 G12C
Slide 29: Six Launches Support Solid Commercialization Prospects
Six Launches Support Solid Commercialization Prospects GFH375（KRAS G12D inhibitor） GFH276（Pan RAS inhibitor） PDAC PDAC Late-line, mono 1st-line, combo with chemo Late-line, mono NSCLC CRC 1st-line, combo with chemo Late-line, mono 3rd-line, combo with cetux 29
Slide 30: 2026-2027 Planning for Company Pipeline
2026-2027 Planning for Company Pipeline GFH375 GFH276 4 registrational trials 2 registrational trials planned; ongoing or planned MRCT combo ongoing 2L+ PDAC mono, 2L+ NSCLC mono Ph III planning: 2L+ PDAC mono, 1L PDAC（+chemo） 1L PDAC（+chemo）、3L+ CRC（+cetux） China & overseas: combo with chemo or cet
Slide 31: Driving Major-indication Commercialization Through Compliant Marketing
Driving Major-indication Commercialization Through Compliant Marketing Academician Yupei Zhao Honorary President of Peking Union Medical College Hospital Steering committee chairman of Kylin-Wings 01 Study Prof. Lin Shen Peking University Cancer Hospital Leading PI of Kylin-Wings 01 Study Prof. Jun
Slide 32: Innovation, in Expedition
Innovation, in Expedition
GenFleet Therapeutics — H1 2026 Earnings Presentation on 6ix